PsychedelicNewsBreaks – Cybin Corp. CEO Discusses Milestones, Goals and Momentum in Exciting Emerging Industry

September 15, 2020 11:31:31

Cybin, a life-sciences company focused on advancing psychedelic and nutraceutical-based products, today announced that its CEO, Doug Drysdale, is featured in an exclusive audio interview with NetworkNewsWire (“NNW”) – a financial news and content distribution company and one of 50+ brands in the InvestorBrandNetwork (“IBN”). During the interview, Drysdale provides insight into Cybin’s 2020 milestones, near-term goals and its efforts to build on the momentum of an industry that continues to ramp up. “We have secured a source of GMP psilocybin API to support our initial clinical program, and we’ve initiated a program to synthesize our own proprietary API to support future programs,” Drysdale said in the interview. “We’re also very busy on the business development front, and I fully anticipate that we’ll be announcing a number of transactions that potentially expand our development capabilities and add to our IP portfolio.”

To view the full press release, visit

About Cybin Corp.

Cybin is a life-sciences company advancing mushroom-based psychedelic pharmaceuticals and non-psychedelic nutraceutical products for diverse markets as potential therapies for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems aiming to improve bioavailability to achieve the desired effects of psychedelics at low-dosage levels. The new delivery systems will be studied through clinical trials to confirm the safety and efficacy of therapies for major depressive disorder, addictions and cognitive improvement*. For more information, visit the company’s website at

*Cybin makes no medical or treatment claims about its proposed products. Certain statements regarding psilocybin have not been evaluated by the Food and Drug Administration or other similar regulatory authorities, nor has the efficacy of psilocybin been confirmed by FDA-approved research. There is no assurance that psilocybin can be used to diagnose, treat, cure or prevent any disease or condition, and robust scientific research and clinical trials are needed. In addition, Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products are not intended to imply that such claims have been verified in clinical trials or that Cybin will be able to complete such trials. If Cybin is not able to obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on its performance and operations.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at

About PsychedelicNewsBreaks

PsychedelicNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of PsychedelicNewsWire (PNW). NNB keeps you up-to-date on active US Public Companies complementary to PNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.

Please see full disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

PsychedelicNewsWire (PNW)
San Francisco, CO
415.949.5050 Office